EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Discovery

• Publication date

  2014-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-13-0879PMID 24893890PMCID PMC4125473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477))

  2014cited by this paper
• Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

  2014cited by this paper
• Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

  2014influential reference
• DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

  2013cited by this paper
• Single-cell paired-end genome sequencing reveals structural variation per cell cycle

  2013cited by this paper
• Pan-cancer patterns of somatic copy-number alteration

  2013cited by this paper
• Single-cell mutational profiling and clonal phylogeny in cancer

  2013cited by this paper
• TERT Promoter Mutations in Familial and Sporadic Melanoma

  2013cited by this paper
• Highly Recurrent TERT Promoter Mutations in Human Melanoma

  2013cited by this paper
• Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.

  2013cited by this paper
• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

  2013cited by this paper
• A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• Genome-wide copy number profiling of single cells in S-phase reveals DNA-replication domains

  2013cited by this paper
• Diverse mechanisms of somatic structural variations in human cancer genomes.

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013cited by this paper
• TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

  2013cited by this paper
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

  2012cited by this paper
• Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• The Life History of 21 Breast Cancers

  2012cited by this paper
• Genome-Wide Detection of Single-Nucleotide and Copy-Number Variations of a Single Human Cell

  2012cited by this paper
• Genome-Wide Detection of Single-Nucleotide and Copy-Number Variations of a Single Human Cell

  2012cited by this paper
• Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.

  2012cited by this paper
• Evolution of the cancer genome

  2012cited by this paper
• Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm.

  2012cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• Tumour evolution inferred by single-cell sequencing

  2011cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

  2011cited by this paper
• Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• High-resolution mapping of copy-number alterations with massively parallel sequencing

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

  2006influential reference
• Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain

  2006cited by this paper
• Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma

  2006cited by this paper
• Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

  2005cited by this paper
• Somatic mutations of EGFR in colorectal cancers and glioblastomas.

  2004cited by this paper
• Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis.

  2002cited by this paper
• Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

  2000cited by this paper
• Role of the INK4a locus in tumor suppression and cell mortality.

  1996cited by this paper
• Structural alterations of the epidermal growth factor receptor gene in human gliomas.

  1992cited by this paper
• Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.

  1991cited by this paper
• Evolution of Cancer

  1991cited by this paper
• Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected].

  1989cited by this paper
• Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

  1989cited by this paper
• Allelotype of colorectal carcinomas.

  1989cited by this paper
• Allelic Loss in Colorectal Carcinoma

  1989cited by this paper
• Highly Recurrent TERT Promoter Mutations in Human Melanoma

  year unknowncited by this paper

• Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine

  2026cites this paper
• Replication stress increases de novo CNVs across the malaria parasite genome

  2026cites this paper
• Strength through diversity: how cancers thrive when clones cooperate

  2025cites this paper
• Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.

  2025cites this paper
• Drug resistance and tumor heterogeneity: cells and ensembles

  2025cites this paper
• Immunotherapy and targeted therapy for high grade gliomas: current and future directions

  2025cites this paper
• Molecular Biomarkers of Glioma

  2025cites this paper
• Widespread Epistasis between Cancer Driver Mutations and Allele-Specific Copy Number Variations

  2025cites this paper
• EGFR activation and conformational "convergence": an emerging allosteric model from cancer mutations.

  2025cites this paper
• The immunology of brain tumors.

  2025cites this paper
• Research progress of single cell RNA sequencing in nervous system

  2025cites this paper
• Double minutes: exploring the formation and oncogenic roles in cancer progression

  2025cites this paper
• EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

  2025cites this paper
• Neural cell competition sculpting brain from cradle to grave

  2025cites this paper
• Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib

  2025cites this paper
• Spatial heterogeneity in glioblastoma: Decoding the role of perfusion.

  2025cites this paper
• Extrachromosomal DNA–Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma

  2025cites this paper
• Spatial-temporal radiogenomics in predicting neoadjuvant chemotherapy efficacy for breast cancer: a comprehensive review

  2025cites this paper
• Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma

  2024cites this paper
• Pervasive structural heterogeneity rewires glioblastoma chromosomes to sustain patient-specific transcriptional programs

  2024cites this paper
• Extrachromosomal DNA driven oncogene spatial heterogeneity and evolution in glioblastoma

  2024cites this paper
• Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment

  2024cites this paper
• Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities

  2024cites this paper
• Proteomic, Metabolomic, and Fatty Acid Profiling of Small Extracellular Vesicles from Glioblastoma Stem-Like Cells and Their Role in Tumor Heterogeneity

  2024cites this paper
• Current status of precision oncology in adult glioblastoma

  2024cites this paper
• Single-cell transcriptomic analysis identifies downregulated phosphodiesterase 8B as a novel oncogene in IDH-mutant glioma

  2024cites this paper
• The Molecular Landscape of Glioblastoma: Implications for Diagnosis and Therapy

  2024cites this paper
• Replication stress increases de novo CNVs across the malaria parasite genome

  2024cites this paper
• Simplifying synthesis of the expanding glioblastoma literature: a topic modeling approach

  2024cites this paper
• Genetic Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience at a Single Institution

  2024influential citation
• Single-cell omics: experimental workflow, data analyses and applications

  2024cites this paper
• Oncogenic Enhancers in Leukemia.

  2024cites this paper
• Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.

  2023cites this paper
• Scrambling the genome in cancer: causes and consequences of complex chromosome rearrangements

  2023cites this paper
• From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis

  2023cites this paper
• Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas

  2023cites this paper
• Antibody drug conjugates for glioblastoma: current progress towards clinical use

  2023cites this paper
• Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance

  2023cites this paper
• An Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma

  2023cites this paper
• A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.

  2023cites this paper
• An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma

  2023cites this paper
• A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.

  2023cites this paper
• Superenhancers as master gene regulators and novel therapeutic targets in brain tumors

  2023cites this paper
• Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume.

  2023cites this paper
• Insight into spatial intratumoral genomic evolution in glioblastoma

  2023influential citation
• Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?

  2023cites this paper
• Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells.

  2023cites this paper
• A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases

  2023cites this paper
• Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

  2023cites this paper
• Single-cell genome and transcriptome sequencing without upfront whole-genome amplification reveals cell state plasticity of melanoma subclones

  2023cites this paper
• Why has targeting EGFR aberrations in glioblastoma therapy had limited success?

  2022cites this paper
• Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges

  2022cites this paper
• EGFR, the Lazarus target for precision oncology in glioblastoma.

  2022cites this paper
• Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study

  2022cites this paper
• Intestinal cellular heterogeneity and disease development revealed by single-cell technology

  2022cites this paper
• Integrative insights and clinical applications of single-cell sequencing in cancer immunotherapy

  2022cites this paper
• Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma

  2022cites this paper
• Current therapeutic options for glioblastoma and future perspectives

  2022cites this paper
• Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?

  2022cites this paper
• Glioblastoma: Current Status, Emerging Targets, and Recent Advances

  2022cites this paper
• Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma

  2022cites this paper
• Pioneering insights of extrachromosomal DNA (ecDNA) generation, action and its implications for cancer therapy

  2022cites this paper
• Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma

  2022cites this paper
• Applications of single‐cell multi‐omics sequencing in deep understanding of brain diseases

  2022cites this paper
• Pediatric Sarcomas: The Next Generation of Molecular Studies

  2022cites this paper
• Multi-Omics Profiling of the Tumor Microenvironment.

  2022cites this paper
• Targeting immunoliposomes to EGFR-positive glioblastoma

  2022cites this paper
• Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

  2022cites this paper
• Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma

  2022cites this paper
• Coagulation proteases and neurotransmitters in pathogenicity of glioblastoma multiforme

  2022cites this paper
• Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma

  2022cites this paper
• SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances

  2022cites this paper
• Detection of EGFR Mutation Distribution and Transcriptional Variants in IDH-wildtype High-grade Gliomas using a Next-generation Sequencing Oncopanel

  2021cites this paper
• Microfluidics applications for high-throughput single cell sequencing

  2021cites this paper
• Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma

  2021cites this paper
• Sensitivity to copy number variation analysis in single cell genomics.

  2021cites this paper
• Signaling in the tumor microenvironment of therapy-resistant glioblastoma

  2021cites this paper
• Clinical Targeting of Altered Metabolism in High-Grade Glioma

  2021cites this paper
• The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis

  2021cites this paper
• Single-Cell Analysis Using Machine Learning Techniques and Its Application to Medical Research

  2021cites this paper
• Single-cell landscapes of primary glioblastomas and matched organoids and cell lines reveal variable retention of inter- and intra-tumor heterogeneity

  2021cites this paper
• Imaging-Genomics in Glioblastoma: Combining Molecular and Imaging Signatures

  2021cites this paper
• Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution

  2021cites this paper
• Applications of Single-Cell DNA Sequencing.

  2021cites this paper
• Future Perspectives: A Review of Therapeutic Advances in Recurrent Glioblastoma

  2021cites this paper
• Decoding Cancer Biology One Cell at a Time.

  2021cites this paper
• Genetic Architectures and Cell-of-Origin in Glioblastoma

  2021cites this paper
• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

  2021cites this paper
• Diffuse Glioma Heterogeneity and Its Therapeutic Implications.

  2021cites this paper
• EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma

  2021cites this paper
• Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.

  2021cites this paper
• Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

  2021cites this paper
• A Predictive Clinical-Radiomics Nomogram for Survival Prediction of Glioblastoma Using MRI

  2021cites this paper
• Extrachromosomal DNA: An Emerging Hallmark in Human Cancer.

  2021cites this paper
• Telomerase as a therapeutic target in glioblastoma.

  2021cites this paper
• Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?

  2021cites this paper
• The IL13α 2R paves the way for anti-glioma nanotherapy.

  2021cites this paper
• Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications.

  2020cites this paper
• Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective

  2020cites this paper
• BnpC: Bayesian non-parametric clustering of single-cell mutation profiles

  2020cites this paper